CJC-1295 With DAC vs Without DAC: Sustained vs Pulsatile GH Release

CJC-1295 exists in two forms with dramatically different pharmacokinetic profiles despite sharing the same core peptide sequence: the DAC (Drug Affinity Complex) version and the non-DAC version (commonly called Mod GRF 1-29). Both stimulate the anterior pituitary to release growth hormone — but they do so at completely different timescales, with different implications for how the GH axis is engaged.

Side-by-Side

The DAC Modification Explained

The Drug Affinity Complex (DAC) is a maleimidopropionic acid (MPA) moiety attached to a reactive lysine residue on the CJC-1295 peptide chain. After subcutaneous injection, this MPA group forms a covalent bond with Cysteine-34 on human serum albumin — the most abundant plasma protein, with a natural half-life of ~19–21 days.

By hitching a ride on albumin, DAC-modified CJC-1295 effectively borrows albumin's pharmacokinetic profile: half-life extends from ~30 minutes to ~6–8 days — roughly a 300-fold increase in circulating persistence. Research in healthy subjects has shown CJC-1295 with DAC can elevate mean GH levels 2–10× and IGF-1 1.5–3× over baseline for days after a single injection.

Why Pulsatility Matters

Natural GH secretion is pulsatile. The pituitary releases GH in discrete bursts every 3–4 hours, with the largest pulse during slow-wave sleep. This pattern is biologically significant:

• Hepatic GH receptors signal differently under pulsatile vs continuous exposure.
• Sexually dimorphic gene expression depends on pulsatility.
• Optimal IGF-1 regulation and lipolytic signaling rely on the pulse structure, not just total GH load.

Mod GRF 1-29 (No DAC) produces sharp, transient GH spikes resolving in 1–2 hours — closely mimicking natural ultradian rhythm. CJC-1295 With DAC produces a sustained, non-physiological plateau. These are not interchangeable experimental tools.

How to Choose

• Use No DAC (Mod GRF 1-29) when studying GH physiology under conditions that preserve normal pulsatility, when stacking with ipamorelin or another GHSR agonist for pulse-window experiments, or when endpoint interpretation depends on physiological mimicry.
• Use With DAC when the research aim is maximal sustained GH/IGF-1 elevation and pulsatility is not a critical variable.

See the ipamorelin vs CJC-1295 comparison for stack logic framing, which almost always assumes the No DAC form.

Bottom Line

DAC is not a convenience feature — it is a fundamental change to the pharmacology. Sustained continuous exposure and discrete pulsatile exposure are different biological signals. Research design should name which signal the protocol intends to produce, then pick the CJC-1295 form that delivers it.

Educational content only. Not medical advice.